These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39121480)

  • 1. Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers.
    Loi P; Schade AE; Rodriguez CL; Krishnan A; Perurena N; Nguyen VTM; Xu Y; Watanabe M; Davis RA; Gardner A; Pilla NF; Mattioli K; Popow O; Gunduz N; Lannagan TRM; Fitzgerald S; Sicinska ET; Lin JR; Tan W; Brais LK; Haigis KM; Giannakis M; Ng K; Santagata S; Helin K; Sansom OJ; Cichowski K
    Cancer Discov; 2024 Dec; 14(12):2430-2449. PubMed ID: 39121480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic KRAS mutations modulate BAX-mediated cell death.
    Ferreira A; Manon S; Eyitayo AR; Chaves SR; Côrte-Real M; Preto A; Sousa MJ
    Biochim Biophys Acta Mol Cell Res; 2025 Jan; 1872(1):119872. PubMed ID: 39515665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
    Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
    Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.
    Dorard C; Madry C; Buhard O; Toifl S; Didusch S; Ratovomanana T; Letourneur Q; Dolznig H; Garnett MJ; Duval A; Baccarini M
    Oncogene; 2023 May; 42(20):1649-1660. PubMed ID: 37020037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA H19-EZH2 interaction promotes liver fibrosis via reprogramming H3K27me3 profiles.
    Li XJ; Zhou F; Li YJ; Xue XY; Qu JR; Fan GF; Liu J; Sun R; Wu JZ; Zheng Q; Liu RP
    Acta Pharmacol Sin; 2023 Dec; 44(12):2479-2491. PubMed ID: 37580495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers.
    Xiao F; Wang K; Wang X; Li H; Hu Z; Ren X; Huang W; Feng T; Yao L; Lin J; Li C; Zhang Z; Mei L; Zhu X; Zhong W; Xie Z
    Mol Cancer Ther; 2024 Dec; 23(12):1703-1716. PubMed ID: 39087485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of the biological mechanisms of CENPA as an oncogene in glioma: Screening based on cancer functional status.
    Ling Y; Teng W; Long N; Qiu W; Wei R; Hou Y; Jiang L; Liu J; Zhou X; Chu L
    J Cell Mol Med; 2024 Dec; 28(23):e70181. PubMed ID: 39620895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies.
    Zhang J; Yang M; Liu Q; Xue X; Tian S; Hu X; Li M; Li J; Chai Q; Liu F; You X; Zhang Y
    Bioorg Chem; 2024 Dec; 153():107964. PubMed ID: 39571304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The wnt/pyruvate kinase, muscle axis plays an essential role in the differentiation of mouse neuroblastoma cells.
    Lei C; Wang J; Zhang X; Ge X; Zhao W; Li X; Jiang W; Ma M; Wang Z; Sun S; Kong Q; Li H; Mu L; Wang J
    Neurochem Int; 2024 Dec; 181():105901. PubMed ID: 39542042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism.
    Wu X; Adame-Garcia SR; Koshizuka K; Vo PTT; Hoang TS; Sato K; Izumi H; Goto Y; Allevato MM; Wood KC; Lippman SM; Gutkind JS
    Cancer Prev Res (Phila); 2024 Dec; 17(12):571-583. PubMed ID: 39463147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel diaryl urea-oxindole hybrids as BRAF kinase inhibitors targeting BRAF and KRAS mutant cancers.
    Ghannam IAY; El Kerdawy AM; Mounier MM; Abo-Elfadl MT; Abdel-Mohsen HT
    Bioorg Chem; 2024 Dec; 153():107848. PubMed ID: 39368145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Coppedè F; Lopomo A; Spisni R; Migliore L
    World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yes-associated protein indispensably mediates hirsutine-induced inhibition on cell growth and Wnt/β-catenin signaling in colorectal cancer.
    Ren Z; Su R; Liu D; Wang Q; Liu S; Kong D; Qiu Y
    Phytomedicine; 2024 Dec; 135():156156. PubMed ID: 39437684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP7 facilitates deubiquitination of LRRC42 in colorectal cancer to accelerate tumorigenesis and augment Wnt/β-catenin signaling.
    Li Y; Sun X; Huang Z
    Biochim Biophys Acta Mol Cell Res; 2025 Jan; 1872(1):119859. PubMed ID: 39393471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 contributes to sepsis-induced acute lung injury through regulating macrophage polarization.
    Wang Z; Guo Z; Wang X; Chai Y; Wang Z; Liao H; Chen F; Xia Y; Wang X; Wang Z
    Biochim Biophys Acta Mol Basis Dis; 2025 Jan; 1871(1):167554. PubMed ID: 39471914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell hiding in colorectal cancer: correlation with response to chemotherapy in vitro and in vivo.
    Druzhkova I; Potapov A; Ignatova N; Bugrova M; Shchechkin I; Lukina M; Shimolina L; Kolesnikova E; Shirmanova M; Zagaynova E
    Sci Rep; 2024 Nov; 14(1):28762. PubMed ID: 39567584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.
    Tinsley SL; Chianis ERD; Shelley RA; Mall GK; Dhiman A; Baral G; Kothandaraman H; Thoma MC; English IA; Daniel CJ; Acosta LCS; Solorio L; Atallah Lanman N; Pasca di Magliano M; Narla G; Dykhuizen EC; Sears RC; Allen-Petersen BL
    Oncogene; 2024 Dec; 43(50):3673-3687. PubMed ID: 39443726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of NLRP3 inflammasome and Caspase-3/4/11 by 2',4'-dihydroxychalcone contributes to anti-colorectal cancer.
    Zhang G; Yao Y; Zhang Z; Xiao J; Yu H; Zhao J; Yao C; Wang Y; Luo H
    Phytomedicine; 2024 Dec; 135():156194. PubMed ID: 39520954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.
    Valladares-Ayerbes M; Safont MJ; González Flores E; García-Alfonso P; Aranda E; Muñoz AL; Falcó Ferrer E; Cirera Nogueras L; Rodríguez-Salas N; Aparicio J; Llanos Muñoz M; Pimentel Cáceres PP; Castillo Trujillo OA; Vidal Tocino R; Salgado Fernández M; Salud-Salvia A; Massuti Sureda B; Garcia-Carbonero R; Vicente Conesa MÁ; Lloansí Vila A;
    Clin Transl Oncol; 2024 Oct; 26(10):2640-2651. PubMed ID: 38642257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits.
    Galea CA; Wang Y; Sivakolundu SG; Kriwacki RW
    Biochemistry; 2008 Jul; 47(29):7598-609. PubMed ID: 18627125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.